Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

ConditionsWaldenström's Macroglobulinemia Chronic Lymphocytic Leukemia Marginal Zone Lymphoma Follicular Lymphoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsoriOMEDICO AG

About this trial

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

Eligibility criteria

Qualifiers

Waldenström's macroglobulinemia (all treatment lines) OR

Chronic lymphocytic leukemia (all treatment lines) OR

Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy)

Follicular lymphoma (≥3 treatment line)

Disqualifiers

Contraindications according to SmPC for patients with WM, CLL, MZL or FL

Participation in an interventional clinical trial during zanubrutinib treatment.

Trial design

Treatments tested in this trial

Zanubrutinib
Obinutuzumab

Treatment groups

705 Participants

are divided into 4 treatment groups

Sponsors and collaborators

iOMEDICO AG

Lead sponsor

BeOne Medicines I GmbH Switzerland

Collaborator

Source ClinicalTrials.gov